Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.
Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.
Humacyte (Nasdaq: HUMA) announced the publication of clinical outcomes in the Journal of Vascular Surgery for patients treated with Symvess™, their FDA-approved bioengineered human tissue vascular conduit. The study focused on 12 patients with hospital-acquired vascular complications from their V005 pivotal Phase 2/3 clinical trial.
Key results showed 92% secondary patency (blood flow) at an average follow-up of 23.3 months, with 100% limb salvage and zero conduit infections. The patients required arterial repair due to various complications including vascular interventions, tumor resections, and orthopedic surgery injuries. Symvess received full FDA approval in December 2024 for use in adults requiring urgent revascularization for extremity arterial injury.
Humacyte (Nasdaq: HUMA) reported Q2 2025 financial results and business updates. The company generated $301,000 in revenue for Q2 2025 and $818,000 for H1 2025. Key highlights include 82 civilian hospitals now approved to purchase Symvess™, and ECAT approval making the product available to 35 Military Treatment Facilities and 160 VA hospitals.
The company implemented cost reduction measures, including a 30-employee workforce reduction, expecting to save approximately $50 million through 2026. Q2 resulted in a net loss of $37.7 million, with cash position of $88.4 million as of June 30, 2025. July product sales of $0.3 million exceeded total H1 sales, showing commercial momentum.
Clinical progress includes positive V007 Phase 3 trial results for dialysis access, particularly strong in high-risk subgroups, and achievement of 100-patient enrollment in the V012 Phase 3 trial.
Humacyte (Nasdaq: HUMA), a clinical-stage biotechnology company focused on developing bioengineered human tissue, has scheduled its Q2 2025 financial results and corporate update for August 11, 2025, at 8:00 AM ET.
The company will host a conference call and webcast, accessible to U.S. investors at 1-877-704-4453 and international investors at 1-201-389-0920 using Conference ID 13754596. The webcast will be available 15 minutes before the call and remain accessible for at least 30 days afterward on the company's investor relations website.
Humacyte (Nasdaq: HUMA) announced its first sale of Symvess to a U.S. Military Treatment Facility, following its recent Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency. The facility serves approximately 200,000 active-duty service personnel, retirees, and family members.
Symvess, an acellular tissue engineered vessel approved by the FDA in December 2024 for extremity vascular trauma, is now available to approximately 35 Military Treatment Facilities and 160 U.S. Department of Veterans Affairs hospitals through the ECAT system, which provides DOD and other federal agencies access to medical products.
Humacyte (Nasdaq: HUMA) has received Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency for its Symvess product. This approval enables healthcare professionals at Department of Defense (DOD) and Veterans Affairs facilities to access Symvess for treating military service members, veterans, and other patients.
Symvess, an acellular tissue engineered vessel, received FDA approval in December 2024 for extremity vascular trauma indication. The ECAT system integration represents a significant milestone in making the product accessible to military healthcare providers. However, for uses beyond the FDA-approved indication, Symvess remains investigational and requires further regulatory approval.
Humacyte (NASDAQ: HUMA), a commercial-stage biotechnology company focused on developing universally implantable, bioengineered human tissues, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place at the Nasdaq World Headquarters in New York on May 20, 2025.
The company's Founder, President, and CEO, Laura Niklason, M.D., Ph.D., will participate in a fireside chat at 12:30 p.m. EST. Management will also be available for one-on-one meetings. A webcast replay will be accessible through the Events & Presentations section of Humacyte's website.
Humacyte (NASDAQ: HUMA), a clinical-stage biotechnology company focused on developing universally implantable, bioengineered human tissue, has scheduled its Q1 2025 financial results release and corporate update for May 13, 2025. The company will host a conference call and webcast at 8:30 AM ET.
U.S. investors can join via 1-877-704-4453, while international participants can dial 1-201-389-0920 using conference ID 13753487. The webcast will be available 15 minutes before the call and remain accessible on the company's investor relations website for at least 30 days afterward.